Key result
SGLT2 inhibitors show promise for improving pulmonary artery pressure and functional outcomes in HF-associated PH.
Why the study?
The treatment landscape for pulmonary hypertension is evolving, with SGLT2 inhibitors emerging as a potential fourth treatment pathway alongside traditional therapies.
Do SGLT2 inhibitors improve outcomes in patients with pulmonary hypertension?
Do SGLT2 inhibitors improve outcomes in patients with pulmonary hypertension?
SGLT2 inhibitors are emerging as a potential new therapeutic pathway for the management of pulmonary hypertension.
May support SGLT2 inhibitor evaluation in heart failure with pulmonary hypertension; hypothesis-generating and requires randomized confirmation before practice change.
The landscape of pulmonary hypertension (PAH) treatment is evolving, with SGLT2 inhibitors being recognized as a potential fourth treatment pathway alongside traditional therapies. Their incorporation into treatment strategies for PAH could represent a significant shift in management approaches.
No takes yet. Share an insight, caveat, or question.
Memarian et al. (2025) conducted a review in Pulmonary hypertension. SGLT2 inhibitors was evaluated. SGLT2 inhibitors show promise in improving pulmonary artery pressure and functional outcomes in patients with heart failure and associated pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: